Research programme: remyelinating therapies - Inception 5/RocheAlternative Names: Multiple sclerosis therapeutics - Inception 5/Roche
Latest Information Update: 28 Jul 2016
At a glance
- Originator Inception 5; Roche
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Multiple sclerosis
Most Recent Events
- 23 Jun 2014 Early research in Multiple sclerosis in Switzerland (unspecified route)
- 23 Jun 2014 Early research in Multiple sclerosis in USA (unspecified route)